Abstract：
The integration of a large number of drugs, such as antineoplastic agents and cancer-related supportive care drugs, into the management of cancer patients exposes them to an increased number of drug-related problems (DRP). Clinical pharmacists contribute to drug management by actively intervening in detected DRP. The aim of this study is to assess the impact of the applying a clinical pharmacist-driven comprehensive medication management (CMM) service to onco-hematology patients. This prospective interventional study was carried out over six-month duration, specifically from November 06, 2022 to April 5, 2023 in the oncology and hematology departments of the EHU Oran. The adherence to treatment was evaluated using the 8-item Morisky Medication Adherence Scale (MMAS). Whereas data related to the patient\'s general condition and medication history was assessed using the Pharmaceutical Care Network Europe (PCNE) Classification for Drug-Related Problems V9.1. Among the 130 patients included in the study, a total of 879 DRP were identified, with a mean of 6.78 (±1.72) DRP/patient, half of which were related to efficacy (51%). Almost half of our sample (44.6%) did not adhere to their treatment. The most frequent cause of DRP, accounting for (19.9%) of the cases, was the inappropriate administration by a health professional. A total of 875 pharmaceuticals interventions (PI) were proposed, 67.2% of which were focused at the drug level. The PI acceptance rate was 94.1%. The integration of CMM services in onco-hematology played an important role in optimizing dosing regimen and treatment administration methods, as well as preventing iatropathology in the management of cancer patients.
摘要：
大量药物的整合，如抗肿瘤药物和癌症相关的支持治疗药物，癌症患者的管理使他们面临越来越多的药物相关问题（DRP）。临床药师通过积极干预检测到的DRP，为药物管理做出贡献。这项研究的目的是评估将临床药师驱动的综合药物管理（CMM）服务应用于Onco血液学患者的影响。这项前瞻性干预研究持续了六个月，特别是从2022年11月6日至2023年4月5日在EHUOran的肿瘤和血液科。使用8项Morisky药物依从性量表（MMAS）评估对治疗的依从性。而与患者的一般状况和用药史相关的数据是使用欧洲药物护理网络(PCNE)药物相关问题分类V9.1进行评估的。在纳入研究的130名患者中，总共确定了879个DRP，平均为6.78（±1.72）DRP/患者，其中一半与疗效相关(51%)。我们的样本中几乎有一半(44.6%)没有坚持他们的治疗。DRP最常见的原因,占(19.9%)的病例，是卫生专业人员的不当管理。总共提出了875项药物干预措施(PI)，其中67.2%集中在药物水平。PI接受率为94.1%。整合CMM服务在优化给药方案和治疗管理方法方面发挥了重要作用,以及在癌症患者的管理中预防医学病理学。
